The FDA’s advisory panel voted unanimously Friday that booster doses of the Pfizer vaccine should be available to people 65 and older and people at high risk of severe disease. That recommendation is likely to be amended to include other groups like healthcare workers. Assuming the FDA uses the panel’s recommendation,…
